C07K 5/021
Containing the structure -nh-n-c-, n being 5 or 6
Official title: {containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds}
C07K5/021 (Containing the structure -nh-n-c-, n being 5 or 6) appears on 223 US grants and 141 published applications in this corpus.
Search patents in C07K- Granted patents
- 223
- Published applications
- 141
- Assignees
- 113
- Inventors
- 519
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 7 | 0 |
| 1993 | 3 | 0 |
| 1994 | 7 | 0 |
| 1995 | 6 | 0 |
| 1996 | 19 | 0 |
| 1997 | 27 | 0 |
| 1998 | 14 | 0 |
| 1999 | 9 | 0 |
| 2000 | 13 | 0 |
| 2001 | 8 | 2 |
| 2002 | 9 | 9 |
| 2003 | 4 | 7 |
| 2004 | 7 | 12 |
| 2005 | 6 | 7 |
| 2006 | 5 | 8 |
| 2007 | 4 | 4 |
| 2008 | 6 | 4 |
| 2009 | 4 | 3 |
| 2010 | 6 | 4 |
| 2011 | 1 | 5 |
| 2012 | 2 | 1 |
| 2013 | 4 | 7 |
| 2014 | 5 | 5 |
| 2015 | 6 | 4 |
| 2016 | 7 | 10 |
| 2017 | 5 | 5 |
| 2018 | 1 | 8 |
| 2019 | 3 | 4 |
| 2020 | 1 | 7 |
| 2021 | 6 | 5 |
| 2022 | 2 | 5 |
| 2023 | 3 | 7 |
| 2024 | 3 | 3 |
| 2025 | 2 | 2 |
| 2026 | 2 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bispecific antigen binding molecules that bind HER2, and methods of use thereof24 Mar 2026US 12,583,939 B2Regeneron Pharmaceuticals, Inc.
- PSMA-targeting imaging agents10 Mar 2026US 12,569,577 B2The Cleveland Clinic Foundation
- Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues23 Sep 2025US 12,421,276 B2Athira Pharma, Inc.
- Class of functional molecules targeting proteolysis pathways, preparation and application thereof17 Jun 2025US 12,331,059 B2Institute of Materia Medica, Chinese Academy of Medical Sciences
- Tubulysins and protein-tubulysin conjugates19 Nov 2024US 12,144,864 B2Regeneron Pharmaceuticals, Inc.
- Ptp1b/tc-ptp dual inhibitors and protein degraders20 Aug 2026US 2026/0240878 A1Purdue Research Foundation
- Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof13 Aug 2026US 2026/0232825 A1
- Linker, linker-containing antibody drug conjugate, and preparation method therefor and use thereof16 Jul 2026US 2026/0199496 A1Chengdu Chipscreen Newway Biosciences Co., Ltd.
- Conjugates for treating diseases caused by psma expressing cells29 May 2025US 2025/0170253 A1Endocyte, Inc.
- De novo designed macrocyclic oligoamides3 Apr 2025US 2025/0111889 A1University of Washington
Most cited
By later US patents
- Lysosomal enzyme-cleavable antitumor drug conjugates653US 6,214,345 B1Bristol-Myers Squibb Company · 2001
- Retroviral protease inhibiting compounds159US 5,142,056 AAbbott Laboratories · 1992
- Amino acid derivatives114US 5,196,438 AHoffmann-La Roche Inc. · 1993
- Retroviral protease inhibiting compounds109US 5,354,866 AAbbott Laboratories · 1994
- Cyclic cell adhesion modulation compounds101US 5,192,746 ATanabe Seiyaku Co., Ltd. · 1993